A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Participants
Condition: Healthy Volunteer
Intervention: Oseltamivir; Placebo
Intervention description: Oseltamivir will be administered at 100 or 200 mg intravenous BID for 5 days.; Oseltamivir matched placebo will be administered intravenous for 5 days.
Intervention MeSH terms: Oseltamivir
Phase: Phase 1
Study type: Interventional
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 99.0
Sex: All
Minimum age: 18 Years
Maximum age: 45 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      This multi-center, randomized, double-blind, multiple-dose, placebo-controlled,
      parallel-group study will assess the safety and PK of oseltamivir (Tamiflu) and its
      carboxylate metabolite, RO0640802 in healthy participants. Participants will be randomized to
      receive 100 milligrams (mg) oseltamivir, 200 mg oseltamivir, or placebo, all administered
      intravenously twice daily (BID). The anticipated time on study treatment is 5 days.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Participants with Body Mass Index (BMI) 18-34 kilograms per meter square (kg/m^2),
             inclusive

          -  Male participants who are willing to use barrier contraception for the duration of the
             study and for 3 months following the end of treatment

          -  Female participants who are of non-child bearing potential

          -  Female participants who are of child bearing potential utilizing two effective methods
             of contraception for the duration of the study and for 3 months following the end of
             treatment

        Exclusion Criteria:

          -  Evidence of clinically significant disease or disorder (for example, renal, cardiac,
             bronchopulmonary)

          -  Any other condition or disease which would place the participant at undue risk, or
             interfere with the assessment, or with the ability of the participant to complete the
             study

          -  Clinically significant orthostatic hypotension present at screening or history of
             clinically significant hypotensive episodes or symptoms of fainting, dizziness, or
             lightheadedness.

          -  Participants with abnormal electrocardiogram (ECG), bradycardia or mean QTc at
             screening

          -  Positive result for Hepatitis B, Hepatitis C, human immunodeficiency virus (HIV) 1 or
             2 at screening

          -  Renal impairment

          -  Transplant recipients

          -  A known clinically relevant history of allergy or hypersensitivity

          -  Any clinically relevant abnormal laboratory test results

          -  A clinically relevant history of abuse of alcohol or other drugs of abuse

          -  Any major illness within 30 days prior to the screening examination

          -  Smoking of more than 10 cigarettes a day or an equivalent amount of tobacco in the
             form of cigars or pipe

          -  Participation in a clinical study with an investigational drug within 3 months prior
             to Day 1

          -  Donation/loss of more than 500 milliliters (mL) of blood within 3 months prior to Day
             1

          -  Positive pregnancy test at screening or Day -1 and lactating women